Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
Public ClinicalTrials.gov record NCT00694707. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.
Study identification
- NCT ID
- NCT00694707
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 732 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2008 (Actual)
- Primary completion
- Aug 31, 2009 (Actual)
- Completion
- Aug 31, 2009 (Actual)
- Last update posted
- Jun 12, 2019
2008 – 2009
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Forest Investigative Site | Costa Mesa | California | 92626 | — |
| Forest Investigative Site | Long Beach | California | 90813 | — |
| Forest Investigative Site | Oceanside | California | 92056 | — |
| Forest Investigative Site | Paramount | California | 90723 | — |
| Forest Investigative Site | Riverside | California | 92506 | — |
| Forest Investigative Site | Washington D.C. | District of Columbia | 20016 | — |
| Forest Investigative Site | Bradenton | Florida | 34208 | — |
| Forest Investigative Site | Kissimmee | Florida | 34741 | — |
| Forest Investigative Site | Lake Charles | Louisiana | 70601 | — |
| Forest Investigative Site | Baltimore | Maryland | 21202 | — |
| Forest Investigative Site | Flowood | Mississippi | 39232 | — |
| Forest Investigative Site | Bridgeton | Missouri | 63044 | — |
| Forest Investigative Site | Cincinnati | Ohio | 45219 | — |
| Forest Investigative Site | Charleston | South Carolina | 29405 | — |
| Forest Investigative Site | Memphis | Tennessee | 28117 | — |
| Forest Investigative Site | Houston | Texas | 77008 | — |
| Forest Investigative Site | Houston | Texas | 77021 | — |
| Forest Investigative Site | Irving | Texas | 75062 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00694707, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 12, 2019 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00694707 live on ClinicalTrials.gov.